3 verified publications on file. Each one was read back from PubMed before it was listed, and each states the experimental model it used.
Every paper below studies thymosin beta-4, the full-length 43-amino-acid protein. Much of what is sold as 'TB-500' is the shorter LKKTETQ fragment, which is a different molecule. Research on the protein is not automatically research on the contents of the vial - confirm from the COA which one a product contains.
Regulatory status: TB-500 is not an FDA-approved drug; the FDA lists 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' among bulk drug substances that may present significant safety risks (Category 2) for compounding, page content current as of 04/22/2026.
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK
ModelRat full-thickness wound model, plus keratinocyte migration assays (Boyden chamber)
Philp D, Goldstein AL, Kleinman HK
ModelNormal and aged rodents
Dube KN, Smart N
ModelNarrative review of developmental, repair and vascular-protection literature
Citations are transcribed from the publisher record on PubMed and re-checked when a compound page is updated. Found an error or a study we should add? Tell us — corrections are published, not quietly patched.